Pfizer withdrew Oxbryta (voxelotor), a conditionally approved oral therapy for SCD, saying its benefits don't outweigh risks.
The withdrawal comes after postmarketing studies showed that the risks of side effects were greater than the benefits.
The U.S. Food and Drug Administration on Thursday alerted patients and healthcare professionals about the withdrawal of ...
Pfizer anticipates revenue growth, driven by oncology investments, M&A activities, and manufacturing optimization. See why ...
This summary highlights major health news, including Bavarian Nordic's UNICEF agreement for mpox vaccines, Pfizer's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback